KTC
VNDA icon

Kistler-Tiffany Companies’s Vanda Pharmaceuticals VNDA Stock Holding History

Kistler-Tiffany Companies’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$5K – 583
2018
Q4 		$5K Hold
200
– – ﹤0.01% 485
2018
Q3 		$5K Hold
200
– – ﹤0.01% 500
2018
Q2 		$4K Hold
200
– – ﹤0.01% 500
2018
Q1 		$3K Hold
200
– – ﹤0.01% 526
2017
Q4 		$3K Hold
200
– – ﹤0.01% 516
2017
Q3 		$4K Hold
200
– – ﹤0.01% 464
2017
Q2 		$3K Hold
200
– – ﹤0.01% 461
2017
Q1 		$3K Buy
+200
New +$2.85K ﹤0.01% 465

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kistler-Tiffany Companies's VNDA Position: Q1 2019 in Review

Kistler-Tiffany Companies sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 200 shares — an estimated $5K sold.

Kistler-Tiffany Companies first reported a position in VNDA in Q1 2017 and held it in 8 quarters. The position peaked at $5K in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • Kistler-Tiffany Companies reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 200 Vanda Pharmaceuticals shares in Q1 2019, an estimated $5K.
  • Kistler-Tiffany Companies first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 8 quarters.
  • Kistler-Tiffany Companies's Vanda Pharmaceuticals position peaked at $5K in Q4 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Kistler-Tiffany Companies's 13F filing for Q1 2019, filed 16 Apr 2019.